Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Person

Jay S. Duker

Tracked across 1 events · 22 articles · First seen Aug 21, 2026 · Last active Sep 03, 2026

Sentiment
-70
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 -70
Business
On August 17, 2026, EyePoint Pharmaceuticals announced topline results from LUGANO, the first pivotal Phase 3 clinical trial for DURAVYU (vorolanib intravitreal insert) in wet age-related macular degeneration. The trial failed to meet its prespecified…
Impact: Jay S. Duker, CEO of EyePoint, made optimistic statements about DURAVYU's 'derisked' potential prior to the trial failure, which are now under scrutiny in the investigations.
Aug 21, 2026 · 22 articles
70 Jay S. Duker made confident statementsEyePoint DURAVYU Phase 3...
ERGEN INTELLIGENCE
Track Jay S. Duker live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.